PET/MR vs CECT Scans for Ovarian Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how two types of scans, PET/MR and CECT (Dynamic Enhanced CT), assist doctors in finding and treating ovarian cancer. Both scans capture images inside the body, but the study aims to determine if PET/MR scans more effectively locate tumors, aid in surgery, and predict tumor response to chemotherapy. Suitable candidates for this trial have ovarian cancer or are suspected to have it and can undergo a surgical evaluation to assess tumor removability. As an unphased trial, this study provides a unique opportunity to advance medical imaging techniques for ovarian cancer.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that these imaging techniques are safe for locating ovarian cancer tumors?
Research has shown that PET/MR scans are generally safe and well-tolerated by patients. PET/MR combines different imaging techniques to detect cancerous tumors, providing clear images without causing harm. Studies have found that PET/MR scans effectively detect lesions in the abdomen and pelvis.
Regarding safety, studies have not shown any significant harmful effects from PET/MR scans. Although the procedure involves radiation, exposure is carefully controlled to remain low. Patients usually do not experience serious side effects from the scans.
Similarly, CECT scans (contrast-enhanced computerized tomography) are a standard and safe method in medical imaging. They use a contrast dye to enhance image clarity, which most patients handle well. However, a few individuals might experience mild reactions to the dye, such as a warm sensation or a metallic taste.
Overall, both PET/MR and CECT scans are safe imaging methods with minimal risk for patients.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it compares two advanced imaging techniques, PET/MRI and CECT scans, for evaluating ovarian cancer. Unlike traditional imaging methods, PET/MRI combines metabolic and anatomical data in a single scan, potentially providing more detailed and comprehensive insights into the cancer's characteristics. This could lead to more precise treatment planning and better outcomes for patients. By directly comparing these imaging techniques, the trial aims to determine which method offers superior accuracy and effectiveness in diagnosing and monitoring ovarian cancer.
What evidence suggests that PET/MR and CECT scans are effective for locating ovarian cancer tumors?
This trial will compare the effectiveness of CECT scans with PET/MR scans for diagnosing ovarian cancer. Studies have shown that MRI scans effectively diagnose ovarian cancer, correctly identifying the disease in 91% of cases and ruling it out in 85% of cases. Researchers are exploring PET/MR, which combines two types of scans, for its ability to locate tumors more accurately. Research indicates that PET/MR may excel at detecting cancer spread, especially in the abdomen. Accurately spotting tumors is crucial for doctors to plan better treatment. These findings suggest PET/MR could be a promising tool for managing ovarian cancer.12467
Who Is on the Research Team?
Priya R. Bhosale
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults with confirmed or suspected ovarian cancer who can undergo laparoscopic surgery to see if tumors can be removed. They must have a kidney function test (eGFR) over 30. It's not for those allergic to gadolinium, with eGFR under 30, pacemakers, pregnant women, children, weigh over 400 pounds, or high blood sugar.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Patients undergo standard of care CECT scan and PET-MRI scan over 90-120 minutes within 30 days before laparoscopy or cytoreduction.
Chemotherapy
Patients who do not undergo cytoreduction based on diagnostic laparoscopy undergo additional PET-MRI and standard of care CECT scans after completion of chemotherapy and before cytoreduction.
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Dynamic Enhanced CT
- Magnetic Resonance Imaging
- Positron Emission Tomography
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator